Investigator Databank Expands Members and Launches Website
Novartis, Janssen, Merck (MSD outside the United States and Canada), Lilly, and Pfizer have joined with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank.
Novartis, Janssen, Merck (MSD outside the United States and Canada), Lilly, and Pfizer have joined with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank. In addition, investigators can now access the Investigator Databank through the launch of http://www.investigatordatabank.org. Through this website, investigators can securely log in, view and add to their information kept on file by the participating pharmaceutical companies or DrugDev.
The new website http://www.investigatordatabank.org enables the upload of standard essential documents such as CVs, GCP training certificates, and non-study specific site profile forms into a global repository, eliminating some of the repetitive, administrative tasks associated with study feasibility, site qualification, and site start-up.
With five member companies now on board, the Investigator Databank has grown to include nearly 180,000 investigators, 50,000 sites and 7,335 studies.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
